45 Participants NeededMy employer runs this trial

Educational Intervention for Lung Cancer

MT
Overseen ByMatthew Triplette, MD, MPH
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Fred Hutchinson Cancer Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

The trial aims to determine if a new educational program, the Restorative Justice-Based Lung Cancer Screening Decision-Making Support Intervention, can increase lung cancer screenings among Black individuals. By fostering trust and understanding through restorative justice—a method focused on repairing harm and building relationships—the program may enhance screening rates in this community. This is crucial because lung cancer is a leading cause of cancer deaths among Black people, yet screening rates remain low. The trial seeks Black or African American individuals aged 50-77 who have a significant smoking history, particularly within the last 15 years, and who have not had a chest CT scan in the past year. As an unphased trial, it offers a unique opportunity to contribute to innovative approaches that could improve lung cancer screening rates in the community.

Do I need to stop my current medications for this trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What prior data suggests that this intervention is safe?

Research has shown that this program, designed to assist individuals in making decisions about lung cancer screening, particularly supports Black individuals. While direct evidence about its safety is lacking, the program is non-invasive, involving no medical procedures or drugs. Instead, it includes sessions focused on building trust and understanding, suggesting it is likely well-tolerated. As an educational and supportive initiative, it generally poses a low risk of negative effects.12345

Why are researchers excited about this trial?

Researchers are excited about this trial because it explores a novel approach to lung cancer screening decisions through a restorative justice-based intervention. Unlike typical decision-making processes, which may rely heavily on medical data and physician recommendations, this intervention involves a community advisory board and focuses on collaborative, justice-oriented discussions. This approach aims to empower patients by making them active participants in their healthcare choices, potentially leading to more personalized and satisfactory outcomes.

What evidence suggests that this intervention is effective for increasing lung cancer screening among Black individuals?

Research has shown that yearly low-dose chest CT scans for lung cancer screening can reduce lung cancer deaths by 20%. However, fewer individuals from minority groups, including Black individuals, complete these screenings. This trial includes a decision-making support intervention based on restorative justice, aiming to change this by building trust and understanding. It addresses social and historical health inequalities, potentially increasing participation in lung cancer screening. Although specific data on the intervention's effectiveness is limited, it is designed to empower Black community members in making health decisions, which could lead to more people getting screened.12356

Who Is on the Research Team?

MT

Matthew Triplette, MD, MPH

Principal Investigator

Fred Hutch/University of Washington Cancer Consortium

Are You a Good Fit for This Trial?

This trial is for Black or African American adults aged 50-77 who speak English, have smoked the equivalent of a pack a day for 20 years, and currently use tobacco or quit within the last 15 years. It also includes community members and healthcare staff serving this population.

Inclusion Criteria

Proficiency in the English language
Self-reported 20-pack year smoking history
Identify as Black or African American
See 4 more

Exclusion Criteria

Non-English speaking community advisory board (CAB) members
Inability to read written English
I am under 18 years old.
See 2 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Community Advisory Board Meetings

Participants attend CAB meetings over 60 minutes on study in support of the co-development and adaptation of the restorative justice-based LCS decision-making support intervention.

1 session
1 visit (in-person)

Intervention

Participants attend an in-person restorative justice-based LCS decision-making support session over 2-3 hours on study.

1 session
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment, including completion of chest CT within 90 days post-intervention.

Up to 90 days

What Are the Treatments Tested in This Trial?

Interventions

  • Restorative Justice-Based Lung Cancer Screening Decision-Making Support Intervention

Trial Overview

The study tests an educational program based on restorative justice principles to help Black individuals make informed decisions about lung cancer screening. Participants may complete surveys, interviews, and allow review of their health records.

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: Screening [Lung cancer screening (LCS) decision-making support session]Experimental Treatment4 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Fred Hutchinson Cancer Center

Lead Sponsor

Trials
583
Recruited
1,341,000+

Go2 Foundation

Collaborator

AstraZeneca

Industry Sponsor

Trials
4,491
Recruited
290,540,000+

Sir Pascal Soriot

AstraZeneca

Chief Executive Officer since 2012

Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris

Dr. Cristian Massacesi

AstraZeneca

Chief Medical Officer since 2021

MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology

Pascal Soriot

AstraZeneca

Chief Executive Officer since 2012

Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris

Cristian Massacesi

AstraZeneca

Chief Medical Officer since 2021

MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology

Citations

Lung Cancer Screening Decision Tool (LCSDecTool)

This decision support tool provides patients and providers with information, a questionnaire, and resources.

A Restorative Justice-Based Lung Cancer Screening ...

LCS lowers lung cancer death by 20%; however, data shows that LCS completion remains low among minority groups in the United States. The restorative justice- ...

A Restorative Justice-Based Lung Cancer Screening ...

LCS lowers lung cancer death by 20%; however, data shows that LCS completion remains low among minority groups in the United States. The restorative justice- ...

A Restorative Justice-Based Lung Cancer Screening Decision ...

LCS lowers lung cancer death by 20%; however, data shows that LCS completion remains low among minority groups in the United States. The ...

5.

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/40869836/

Effectiveness of Technology-Based Interventions in ...

This study reviews how technology-based interventions have been designed and implemented to promote lung cancer screening (LCS), support shared ...

6.

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/40889250/

The quality of patient decision aids for lung cancer screening

Patient decision aids can be used to support shared decision making, but they need to meet quality standards to minimize the potential for ...